Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Open accessThe DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty. METHODS: In this randomized, double-blind study, we assigned 4541 patients to receive either 10 mg of oral rivaroxaban once daily, beginning after surgery, or 40 mg of enoxaparin subcutaneously once daily, beginning the evening before surgery, plus a placebo tablet or injection. The primary efficacy outcome was the composite of deep-vein thrombosis (either symptomatic or detected by bilateral venography if the patient was asymptomatic), nonfatal pulmonary embolism, or death from any cause at 36 days (range, 30 to 42). The main secondary efficacy outcome was major venous thromboembolism (proximal deep-vein thrombosis, nonfatal pulmonary embolism, or death from venous thromboembolism). The primary safety outcome was major bleeding. RESULTS: A total of 3153 patients were included in the superiority analysis (after 1388 exclusions), and 4433 were included in the safety analysis (after 108 exclusions). The primary efficacy outcome occurred in 18 of 1595 patients (1.1%) in the rivaroxaban group and in 58 of 1558 patients (3.7%) in the enoxaparin group (absolute risk reduction, 2.6%; 95% confidence interval [CI], 1.5 to 3.7; P<0.001). Major venous thromboembolism occurred in 4 of 1686 patients (0.2%) in the rivaroxaban group and in 33 of 1678 patients (2.0%) in the enoxaparin group (absolute risk reduction, 1.7%; 95% CI, 1.0 to 2.5; P<0.001). Major bleeding occurred in 6 of 2209 patients (0.3%) in the rivaroxaban group and in 2 of 2224 patients (0.1%) in the enoxaparin group (P=0.18). CONCLUSIONS: A once-daily, 10-mg oral dose of rivaroxaban was significantly more effective for extended thromboprophylaxis than a once-daily, 40-mg subcutaneous dose of enoxaparin in patients undergoing elective total hip arthroplasty. The two drugs had similar safety profiles. (ClinicalTrials.gov number, NCT00329628.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We identified 1 RCT 317 to inform this recommendation.”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The investigation into the use of the lower doses of these 2 anticoagulants for secondary prevention was prompted by the desire to reduce the risk of bleeding, as well as the documented efficacy of the lower doses to prevent VTE after elective hip or knee arthroplasty. 317-321”
From American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism (2020) · cites this paper as [317]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationThe Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Poller, L., Bussey, H., Jacobson, A., & Hylek, E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.204s · Cited by 1,528
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Self-citationRoentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
Turpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Self-citationRosencher, N., Kerkkamp, H. E. M., Macheras, G., Munuera, L. M., Menichella, G., Barton, D. M., Cremers, S., Abraham, I. L., & Investigation, F. T. O. (2003) · Transfusion · doi:10.1046/j.1537-2995.2003.00348.x · Cited by 603
Eikelboom, J. W., Quinlan, D. J., & Douketis, J. D. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05249-1 · Cited by 513
Research works printed but not linked: 1
- 10.1016/s0140-6736(07)61445-7 · DOI · Paper page
Cited by
Items 801–900 of 1,000
van der Veen, L., van Raay, J. J., Gerritsma-Bleeker, C. L. E., Veeger, N. J. G. M., & van Hulst, M. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-002218 · Cited by 7
Anticoagulant treatment: the end of the old agents?
Graf, L., & Tsakiris, D. A. (2012) · Swiss Medical Weekly · doi:10.4414/smw.2012.13684 · Cited by 7
Low-molecular-weight heparin for thromboprophylaxis
Camporese, G., & Bernardi, E. (2009) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e32832f5d9d · Cited by 7
The Novel Oral Anticoagulants: An Update for the Interventional Radiologist
Crockett, M. T., Moynagh, M. R., & Kavanagh, E. C. (2012) · American Journal of Roentgenology · doi:10.2214/ajr.11.8151 · Cited by 7
“This produced low bleeding rates and satisfactory anticoagulant effect [5].”
BackgroundKonishi, N., Hiroe, K., & Kawamura, M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-12-0817 · Cited by 7
Atrial fibrillation and coagulation: Who and when?
Fitzmaurice, D. A. (2009) · Blood Reviews · doi:10.1016/j.blre.2009.07.006 · Cited by 7
An update on the pharmaceutical management of thrombosis
Cosmi, B. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1241233 · Cited by 8
Serrao, A., Lucani, B., Assanto, G. M., Fiori, L., Baldacci, E., Aprile, S. M., & Chistolini, A. (2020) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-020-02070-2 · Cited by 7
Yao, Y., Li, X., & Qiu, F. (2023) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296231178546 · Cited by 7
Anticlotting agents and the surgical management of glaucoma
Sozeri, Y., & Salim, S. (2017) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000456 · Cited by 7
Fallaha, M. A., Radha, S. S., & Patel, S. (2018) · Patient Safety in Surgery · doi:10.1186/s13037-018-0169-x · Cited by 7
Yang, T., Murillo, M. U., Vadhariya, A., Wilson, A., Putney, D. R., & Muntz, J. E. (2019) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxy080 · Cited by 7
Hong, K. (2019) · Journal of Stroke · doi:10.5853/jos.2019.01970 · Cited by 7
Schmidt, K., Krüger, K., Langer, E., Schmutzler, M., Johnen, E., Wernecke, K. D., von Heymann, C., & Körber, M. K. (2019) · Blood transfusion · doi:10.2450/2018.0028-18 · Cited by 9
Rangarajan, S. (2010) · Haemophilia · doi:10.1111/j.1365-2516.2010.02335.x · Cited by 7
Emerging anticoagulants for venous thromboembolism prevention
Trujillo, T. C. (2010) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp100178 · Cited by 9
“001).(31) There was no significant difference between rivaroxaban and enoxaparin in the incidence of major bleeding (0.”
BackgroundMethodGómez‐Outes, A., Suárez‐Gea, M. L., Blázquez-Pérez, A., Pozo-Hernández, C., & Vargas, E. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03618.x · Cited by 7
Deep Vein Thrombosis and Pulmonary Embolism
Goldhaber, S. Z. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00016-6 · Cited by 8
Hospital Pharmacy Pulse - Recent Publications on Medications and Pharmacy
Sterling, J. A. (2007) · Hospital Pharmacy · doi:10.1310/hpj4206-578 · Cited by 7
Rivaroxaban in the contemporary treatment of acute coronary syndromes
Alexander, D., & Jeremias, A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.580274 · Cited by 6
“The RECORD 1 and 2 trials demonstrated superiority of either shortterm or extended term 10 mg rivaroxaban over 40 mg of daily enoxaparin in preventing DVT or PE in patients undergoing elective hip replacement [55,56].”
BackgroundMcLiesh, P., & Wiechula, R. (2012) · JBI Library of Systematic Reviews · doi:10.11124/jbisrir-2012-30 · Cited by 6
Management of coagulation: an Australian perspective
Weightman, W. M., & Gibbs, N. M. (2011) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32834e46b1 · Cited by 6
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty
Aikens, G. B. (2014) · World Journal of Orthopedics · doi:10.5312/wjo.v5.i3.188 · Cited by 6
Isaacs, A. N., Doolin, M. K., Morse, C., Shiltz, E., & Nisly, S. A. (2016) · American Journal of Health-System Pharmacy · doi:10.2146/sp150031 · Cited by 8
Aspirin thromboprophylaxis in joint replacement surgery
Sharda, A. V., Fatovic, K., & Bauer, K. A. (2022) · Research and Practice in Thrombosis and Haemostasis · doi:10.1002/rth2.12649 · Cited by 6
Shi, P., Zheng, W., Zhou, J., Han, N., & Yin, J. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14143 · Cited by 6
Arrayás, I. G., Fernández, C. S., Cerezo, J. F. G., Nicolás, L. B., de Salas-Cansado, M., & Rubio‐Terres, C. (2012) · PubMed · doi:10.4321/s1135-57272012000600006 · Cited by 6
Rivaroxaban versus high dose nadroparin for thromboprophylaxis after hip or knee arthroplasty
Thermann, H., Heckmann, F., & Heckmann, M. (2015) · Hämostaseologie · doi:10.5482/hamo-14-12-0078 · Cited by 7
“ID: 3353958) for thromboprophylaxis after total hip or knee arthroplasty and to the inclusion of rivaroxaban in clinical guidelines (5, 7, 8, 14, 18).”
BackgroundAnticoagulant therapy with rivaroxaban in a young patient with paroxysmal nocturnal hemoglobinuria
Dragoni, F., Chiarotti, F., Lombardi, L., Iori, A. P., & Cafolla, A. (2015) · Clinical Case Reports · doi:10.1002/ccr3.342 · Cited by 6
“Rivaroxaban is an orally active direct Factor Xa inhibitor, which demonstrated to be effective in the prevention of venous thromboembolism after orthopedic surgery [4].”
BackgroundRomualdi, E., & Ageno, W. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.05.006 · Cited by 6
Top 10 Clinical Research Developments in Antiphospholipid Syndrome
Barbhaiya, M., & Erkan, D. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0367-6 · Cited by 6
Measuring or Monitoring of Novel Anticoagulants: Which Laboratory Test to Request?
Dobesh, P. P., & Terry, K. J. (2013) · Current Emergency and Hospital Medicine Reports · doi:10.1007/s40138-013-0029-z · Cited by 6
Novel drugs for oral anticoagulation pharmacotherapy
Capodanno, D., Giacchi, G., & Tamburino, C. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.18 · Cited by 6
Elwood, D., & Koo, C. (2009) · PM&R · doi:10.1016/j.pmrj.2008.11.012 · Cited by 6
Morell, J., Sullivan, B., Khalabuda, M., & McBride, B. F. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009355814 · Cited by 11
“RECORD 1 tested the hypothesis that 5 to 9 days of postoperative rivaroxaban (10 mg daily) was at least equivalent to 5 to 9 days of enoxaparin 40 mg following total hip replacement.(46,49) The composite primary end point of this trial was the incidence of DVT, nonfatal PE, and all-cause mortality.”
MethodImproving prevention and treatment of venous thromboembolism: clinical trial results
Mahan, C. E., & Spyropoulos, A. C. (2012) · Journal of Medical Economics · doi:10.3111/13696998.2012.667026 · Cited by 6
The place of new oral anticoagulants in travel medicine
Ringwald, J., Grauer, M., Eckstein, R., & Jelínek, T. (2013) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2013.11.005 · Cited by 8
Schmitt, C., Pannier, A., McIntyre, C., Zandt, H., Ciorciaro, C., Winters, K., & Pepper, T. (2011) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011401621 · Cited by 6
“In fact, the first oral FXa inhibitor has recently been approved for the prophylaxis of venous thromboembolism.(20,21) R1663 is an orally available, direct FXa inhibitor in development for the prevention and treatment of thromboembolic diseases.”
BackgroundMahan, C. E., & Kaatz, S. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1133 · Cited by 6
Recent New Drug Approvals, Part 2: Drugs Undergoing Active Clinical Studies in Children
Chhim, R. F., Shelton, C. M., & Christensen, M. L. (2013) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-18.1.14 · Cited by 6
Denas, G., & Pengo, V. (2012) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.668524 · Cited by 6
“2 Rivaroxaban Oral rivaroxaban was compared with subcutaneous enoxaparin for the extended thromboprophylaxis in the setting of orthopedic surgery in the RECORD program [53-56].”
MethodUpdate on Anticoagulation: What the Interventional Radiologist Needs to Know
Kamath, S. D., & McMahon, B. J. (2016) · Seminars in Interventional Radiology · doi:10.1055/s-0036-1582124 · Cited by 6
Yan, X., Gu, X., Zhou, L., Lin, H., & Wu, B. Y. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0444-5 · Cited by 6
Postorthopedic Surgery Joint Replacement Surgery Venous Thromboembolism Prophylaxis
Kwong, L. M., & Kimball, J. A. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.05.001 · Cited by 6
Nuevos anticoagulantes orales: actualización
Berkovits, A., & Mezzano, D. (2017) · Revista chilena de cardiología · doi:10.4067/s0718-85602017000300254 · Cited by 11
Routine coagulation test abnormalities caused by rivaroxaban
Song, Z., Wu, H., Cao, H., Yang, S., Tang, M., & Qin, L. (2018) · Medicine · doi:10.1097/md.0000000000013104 · Cited by 6
“Rivaroxaban is approved for the prevention of stroke in nonvalvular atrial fibrillation (AF),([1]) prevention and treatment of venous thromboembolism (VTE),([2]) and prophylaxis against deep vein thrombosis (DVT) after knee and hip replacement surgery.([3]) It has a predictable anticoagulant effect, eliminating”
Hoffmann, C., Leven, C., Mao, R. L., MOREUIL, C. D., & Lacut, K. (2020) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2020.05.026 · Cited by 9
Goldhaber, S. Z. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0398-6.00077-9 · Cited by 8
Chen, Y., Qin, L., Yang, J., Wang, J., Huang, J., Gong, X., & Hu, N. (2022) · Frontiers in Surgery · doi:10.3389/fsurg.2022.871776 · Cited by 6
“prevention of VTE after TKA due to its effectiveness, high safety and convenience of use (3, 21).”
BackgroundRinaldi, I., Amin, I. F., Shufiyani, Y. M., Dewantara, I. R., Edina, B. C., Winston, K., & Nurrobi, Y. A. S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144070 · Cited by 6
“However, rivaroxaban is commonly associated with bleeding side effects, with the same or higher risks of bleeding observed compared to other thromboprophylaxis agents [5,24,25].”
BackgroundMethodInfluentialRivaroxaban Rebound Acute Coronary Event: A Post Marketing Experience
Agarwal, A. K. (2013) · Cardiology Research · doi:10.4021/cr294w · Cited by 6
“However, during follow-up, eight events (four coronary events) occurred in seven patients in the rivaroxaban group compared to one event in the enoxaparin group [3].”
ResultRivaroxaban for the prevention and treatment of venous thromboembolism
Turpie, A. G. G. (2011) · Fundamental and Clinical Pharmacology · doi:10.1111/j.1472-8206.2011.00980.x · Cited by 6
Samama, M. M., Conard, J., Horellou, M., Flem, L. L., Guinet, C., & Depasse, F. (2010) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2010.08.001 · Cited by 6
Update in perioperative medicine
Smetana, G. W., Cohn, S. L., Mercado, D. L., & Jaffer, A. K. (2006) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2006.00630.x · Cited by 8
Oral factor Xa inhibitors for the long-term management of ACS
Wisler, J. W., & Becker, R. C. (2012) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2012.18 · Cited by 9
New oral anticoagulants to revolutionise venous thromboembolism (VTE) management
Autar, R. (2009) · Journal of Orthopaedic Nursing · doi:10.1016/j.joon.2009.08.002 · Cited by 7
Pannucci, C. J., & Cuker, A. C. (2015) · Aesthetic Surgery Journal · doi:10.1093/asj/sjv129 · Cited by 6
“Similar findings were observed after total hip arthroplasty.(7) Rivaroxaban also offers several practical advantages compared with conventional anticoagulants.”
ResultProphylaxe der venösen Thromboembolie (VTE)
Encke, A., Haas, S. K., Abholz, H. H., Bode, C., Bootz, F., Diener, H. C., Eggeling, S., Eikermann, M., Gerlach, H. E., Gogarten, W., et al. (2016) · VASA · doi:10.1024/0301-1526/a000580 · Cited by 17
Self-citationAvila, L., Ruggiero, E. D., Vincelli, J., & Brandão, L. R. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016681 · Cited by 5
Management of Venous Thromboembolism After Hip and Knee Arthroplasty
Postajian, A., Rostomian, E., Abdou, A., Hatamian, V., Keshishian, S., & Agrawal, D. K. (2025) · Journal of Orthopaedics and Sports Medicine · doi:10.26502/josm.511500210 · Cited by 5
“Direct oral anticoagulants like rivaroxaban and apixaban offer convenient dosing and relatively the strongest VTE protection in patients compared to other mainstay pharmacological interventions including LMWH, with the DVT incidence of 1.1% and 3.7% respectively [86].”
InfluentialZhou, W., Bozenhardt, E., Alexander, G. E., Zierhut, M. L., Merali, S. J., Ajavon‐Hartmann, A., Zannikos, P., Back, H., Suh, E., Goyal, N., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70037 · Cited by 6
Baud, J.-M., Matrand, G., Georges, J., Beaufils, P., & Livarek, B. (2011) · Journal des Maladies Vasculaires · doi:10.1016/j.jmv.2011.10.003 · Cited by 5
“[4] Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, et al.”
The new oral anticoagulants in atrial fibrillation: an update
Verheugt, F. W. A. (2013) · Netherlands Heart Journal · doi:10.1007/s12471-013-0473-0 · Cited by 7
“Finally, oral direct factor Xa blockers have become available and are effective in the prevention and treatment of deep vein thrombosis and pulmonary embolism [13–18].”
BackgroundLes nouveaux anticoagulants dans la maladie thrombo-embolique veineuse
Bertoletti, L., & Mismetti, P. (2011) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2010.12.014 · Cited by 6
[New anticoagulants: dabigatran, rivaroxaban and apixaban].
Ruiz, Á. G. V., López, A. N. R., & Viramontes, M. E. M. (2012) · PubMed · Cited by 9
Antithrombotika und Antihämorrhagika
Hein, L., & Wille, H. (2016) · Springer eBooks · doi:10.1007/978-3-662-50351-5_18 · Cited by 5
Chan, S.-Y., Huang, J., Cheng, C., Hsu, C.-P., Liao, C., & Fu, C. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000778 · Cited by 5
Current Evidence and Expert Opinion on Thromboprophylaxis After Total Knee and Hip Replacement
Mody, B. S., Wadhwa, M., Roy, R., & Echila, S. (2023) · Cureus · doi:10.7759/cureus.51089 · Cited by 8
Rupin, A., MARX, I., Vallez, M. O., Mennecier, P., Gloanec, P., Nanteuil, G. D., & Verbeuren, T. J. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2011.04286.x · Cited by 5
Dosing of rivaroxaban by indication: getting the right dose for the patient
Escolar, G., Carné, X., & Arellano‐Rodrigo, E. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1085022 · Cited by 5
“Based on four Phase II dose-ranging studies in approximately 2900 patients undergoing total hip or knee replacement surgery [15-17,36,55], rivaroxaban 10 mg od was selected for investigation in the Phase III RECORD 1 -- 4 studies [23-26].”
BackgroundMethodInfluentialAcevedo, C. C., Velasco, F., & Herrera, C. (2015) · Future Cardiology · doi:10.2217/fca.15.38 · Cited by 5
New and Emerging Anticoagulant Therapies for Venous Thromboembolism
Linkins, L., & Weitz, J. I. (2010) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-010-0067-8 · Cited by 5
“In RECORD 1, patients undergoing THR were given rivaroxaban or enoxaparin, 40 mg daily(withthe firstdosegiventheeveningbeforesurgery),for31to39days [ 26 ].”
MethodAnti-thrombosis effect of LRRFIP1 shRNA lentivirus in a mouse model of deep vein thrombosis
Yin, X., Wu, S., Wang, Z., Wang, Y., Du, Q., & Wang, A. (2013) · Thrombosis Research · doi:10.1016/j.thromres.2013.05.013 · Cited by 5
“1% [2].”
Haemostatic challenges in the cancer patient: Focus on the perioperative period
Burbury, K. (2013) · Best practice & research. Clinical anaesthesiology · doi:10.1016/j.bpa.2013.09.001 · Cited by 7
Using New Oral Anticoagulants in Patients Undergoing Major Orthopedic Surgery
Bass, A. R. (2015) · Current Rheumatology Reports · doi:10.1007/s11926-015-0498-z · Cited by 5
Pharmacological thromboprophylaxis and total hip or knee replacement
Frostick, S. P. (2016) · British Journal of Nursing · doi:10.12968/bjon.2016.25.1.45 · Cited by 6
Squizzato, A., Romualdi, E., Dentali, F., & Ageno, W. (2010) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0b013e32833f9ea6 · Cited by 5
Drug and herbal/dietary supplements-induced liver injury: A tertiary care center experience
Siddique, A., Siddique, O., Einstein, M. M., Sotil, E. U., & Ligato, S. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i5.207 · Cited by 5
Liesdek, O. C. D., Urbanus, R. T., de Heer, L. M., Fischer, K., Suyker, W. J. L., & Schutgens, R. E. G. (2021) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0041-1722846 · Cited by 6
Chen, J., Lv, M., Jiang, S., Wu, S., Xu, W., Qian, J., Zeng, Z., Chen, M., Fang, Z., & Zhang, J. (2022) · Vascular Medicine · doi:10.1177/1358863x221115213 · Cited by 5
Vélaz, O. A., & Bueno, I. C. (2023) · Revista Española de Cirugía Ortopédica y Traumatología · doi:10.1016/j.recot.2025.01.005 · Cited by 5
The proof for new oral anticoagulants: clinical trial evidence
Huisman, M. V. (2011) · European Orthopaedics and Traumatology · doi:10.1007/s12570-011-0063-9 · Cited by 6
Self-citationAkwaa, F., & Spyropoulos, A. C. (2013) · Hospital Practice · doi:10.3810/hp.2013.02.1008 · Cited by 6
The New Era of Anticoagulation
Skeik, N., Rumery, K. K., & Rodriguez, G. T. (2013) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2013.07.013 · Cited by 8
Tratamiento con anticoagulantes orales: inicio, ajuste y precauciones en su utilización
Expósito, M. C. (2010) · Avances en Diabetología · doi:10.1016/s1134-3230(10)61004-6 · Cited by 13
Novel oral anticoagulants for the prevention of venous thromboembolism in surgical patients
Riva, N., Donadini, M. P., Bozzato, S., & Ageno, W. (2013) · Thrombosis Research · doi:10.1016/s0049-3848(13)70026-4 · Cited by 6
Uso de los anticoagulantes orales directos en la práctica clínica
Salamanca, R. G. J., Gómez, J. D. J., & Roa, A. E. P. (2016) · Revista de la Facultad de Medicina · doi:10.15446/revfacmed.v64n2.49963 · Cited by 9
Kapetanou, A., Savvidis, M. S., Potoupnis, M. E., Petsatodis, G. E., Kirkos, J. M., & Kapetanos, G. A. (2017) · Journal of Frailty Sarcopenia and Falls · doi:10.22540/jfsf-02-001 · Cited by 5
Seoane, L., Cortes, M. M., Cancela, M. E. A., Furmento, J., Baranchuk, A. M., & Conde, D. G. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1484281 · Cited by 5
Hemostatic profile under fluid resuscitation during rivaroxaban anticoagulation: an in vitro survey
Helin, T., Zuurveld, M. G., Manninen, M. J., Meijers, J. C. M., Lassila, R., & Brinkman, H. J. M. (2018) · Transfusion · doi:10.1111/trf.14933 · Cited by 5
Patriquin, C. J., & Crowther, M. A. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00026-9 · Cited by 7
Deng, Z., Zhang, Z., Sheng, P., Fu, M., Xu, D., He, A., Liao, W., & Kang, Y. (2020) · Medicine · doi:10.1097/md.0000000000022028 · Cited by 5
“While we found no evidence to compare in VTE or other complications, future prospective studies should continue to explore rates of adverse eventswith such anticoagulants ormore after anti-fibrinolysiswith multiple boluses of TXA in THA.”
BackgroundInfluentialProfilaxia do tromboembolismo venoso nas cirurgias do tornozelo e do pé
Zambelli, R., Pereira, M. B., & Rezende, S. M. (2020) · Revista Brasileira de Ortopedia · doi:10.1055/s-0040-1715512 · Cited by 9
Shantsila, E., & Lip, G. Y. H. (2015) · Springer eBooks · doi:10.1007/978-3-319-25460-9_3 · Cited by 5
Verolino, P., Sagnelli, C., Grella, R., Nicoletti, G. F., Sica, A., & Faenza, M. (2022) · Healthcare · doi:10.3390/healthcare10030476 · Cited by 5
Abdulrehman, J., Forté, S., TOMLINSON, G. A., Solh, Z., Bolster, L., Sun, H., Bartolucci, P., & Kuo, K. H. M. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-079363 · Cited by 5
Newer Anticoagulants in Critically Ill Patients
Rajasekhar, A., Beyth, R. J., & Crowther, M. A. (2012) · Critical Care Clinics · doi:10.1016/j.ccc.2012.04.005 · Cited by 6
Khosravi‐Shahi, P., & Pérez-Manga, G. (2009) · Clinical Drug Investigation · doi:10.2165/11315310-000000000-00000 · Cited by 5
“This direct inhibitor of FXa has shown efficacy in the prevention and treatment of VTE associated with orthopaedic surgery (total elective hip replacement) and also does not require laboratory monitoring.([43]) Although it is possible that the oral anticoagulants may provide greater convenience than currently availabl…”
BackgroundMohamed (2012) · Current Research in Medicine · doi:10.3844/amjsp.2012.126.129 · Cited by 5
Rivaroxaban, the first oral, direct factor Xa inhibitor
Fassiadis, N. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903413559 · Cited by 5
“, similar rates for bleeding, adverse cardiovascular events and liver dysfunction) [7-10].”
Background
Metadata
- Authors
- Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., & Geerts, W.
- Affiliations
- Sahlgrenska University Hospital (SE)
- Aarhus University Hospital (DK)
- Medical University of South Carolina (US)
- Technical University of Munich (DE)
- Leiden University Medical Center (NL)
- Queen Mary University of London (GB)
- Bayer (Germany) (DE)
- University of Toronto (CA)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-06-26
- Volume
- 358
- Issue
- 26
- Pages
- 2765-2775
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2014491911
- Cited by
- 1,433
- References
- 25
- Citations by year
- 2026: 15 · 2025: 28 · 2024: 24 · 2023: 35 · 2022: 39 · 2021: 55 · 2020: 47 · 2019: 47 · 2018: 60 · 2017: 68 · 2016: 86 · 2015: 92 · 2014: 98 · 2013: 167 · 2012: 159
- FWCI
- 76.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IrInSubria (University of Insubria) (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich) (submittedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Keywords
- rivaroxaban, enoxaparin, thromboprophylaxis, total hip arthroplasty, venous thromboembolism, deep vein thrombosis, pulmonary embolism, factor Xa inhibitors, major bleeding, postoperative anticoagulation
- MeSH terms
- Rivaroxaban, Adolescent, Adult, Aged, Aged, 80 and over, Anticoagulants, Double-Blind Method, Female, Humans, Male, Middle Aged, Morpholines, Pulmonary Embolism, Thiophenes, Enoxaparin, Arthroplasty, Replacement, Hip, Venous Thrombosis, Venous Thromboembolism, Factor Xa Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.